NewsBenzingaEvommune Presents Additional Data From Phase 2a Proof-Of-Concept Trial Of EVO301 In Adults With Atopic Dermatitis At EADV 2026 Congress; Plan To Initiate Subcutaneous Phase 2b Dose-Ranging Trial In Mid-2027 Evommune Presents Additional Data From Phase 2a Proof-Of-Concept Trial Of EVO301 In Adults With Atopic Dermatitis At EADV 2026 Congress; Plan To Initiate Subcutaneous Phase 2b Dose-Ranging Trial In Mid-2027 Benzinga 2026.10.01 12:08 (GMT+0) Open on Benzinga Other news CrowdStrike-Zscaler Reported Merger Talks Could Spark One of Cybersecurity’s Biggest Deals Ever: ZS Stock Jumps, CRWD Falls After Hours Trump Approval Drops to 37% As Cost of Living Tops Voters' Priorities Global Interactive Q3 EPS $(0.16) Up From $(0.17) YoY, Sales $27.000 Down From $1.828K YoY 'Lutnick asked battery startup Pure Lithium to accept US takeover, documents and source say'- Reuters Exclusive Exicure Q3 Adj. EPS $(0.01) Up From $(0.39) YoY Momentus Q3 EPS $(0.40) Misses $(0.36) Estimate, Sales $4.816M Beat $2.600M Estimate
CrowdStrike-Zscaler Reported Merger Talks Could Spark One of Cybersecurity’s Biggest Deals Ever: ZS Stock Jumps, CRWD Falls After Hours
'Lutnick asked battery startup Pure Lithium to accept US takeover, documents and source say'- Reuters Exclusive